A Agilent Technologies Inc.

Agilent Technologies Presents Early Career Professor Award to Dr. Gary Patti

Agilent Technologies Inc. (NYSE:A) has named Dr. Gary J. Patti, as the recipient of the prestigious 2017 Agilent Early Career Professor Award.

Dr. Patti, Associate Professor, Department of Chemistry in Arts and Sciences, Washington University in St. Louis, was selected for his contributions to the detection of metabolomics changes in whole organisms and their utility for drug discovery, early detection, characterization and surveillance of cancer as well as other diseases and conditions.

Using state-of-the-art mass spectrometers coupled with cutting-edge metabolomic technologies, Dr. Patti’s lab takes a systems-level approach to the study of comprehensive metabolism and identification of specific pathways that are altered in connection with particular phenotypes.

“Agilent is pleased to recognize and support the work of Dr. Patti, who is developing and implementing experimental approaches that advance metabolomics analysis from the lab bench to translational applications in human disease,” said Jack Wenstrand, Director, University Relations and External Research at Agilent.

"Metabolism is one of the most exciting areas in biochemical research. We are honored to have one of the world's best in metabolomics here in our department," said Dr. William Buhro, Chairman, Department of Chemistry; George E. Pake Professor in Arts & Sciences, Washington University in St. Louis

The annual Agilent Early Career Professor Award was established in 2008. Through this award, Agilent seeks to recognize the achievements of academic researchers in the initial stages of their careers and to support and develop strong collaborative relationships with them at the beginning of their professional lives. This award underscores Agilent's commitment to furthering research through the company's products and services, financial support, and collaborative engagement by Agilent scientists and engineers.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A), is a global leader in life sciences, diagnostics and applied chemical markets. With more than 50 years of insight and innovation, Agilent instruments, software, services, solutions, and people provide trusted answers to its customers’ most challenging questions. The company generated revenues of $4.20 billion in fiscal 2016 and employs about 13,000 people worldwide. Information about Agilent is available at www.agilent.com.

EN
10/07/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Agilent Technologies Inc.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

 PRESS RELEASE

Agilent xCELLigence RTCA Instrumentation Applied in Recent FDA Approva...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) is pleased to announce its role in supporting Autolus Therapeutics’ , a recently approved CAR T therapy. Agilent's advanced cell analysis instrumentation, specifically the technology, was applied in developing and validating AUCATZYL. The xCELLigence RTCA technology supported the development and implementation of the potency assay. By providing precise and reliable cell analysis solutions, Agilent assisted Autolus in achieving the high standards required for FDA approval. Dr. Xiaobo Wang, Vice President and General Manager of the Cell Functio...

 PRESS RELEASE

CORRECTING and REPLACING Agilent to Showcase Next-Generation Digital P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- Please replace the release with the following corrected version due to multiple revisions to the fifth paragraph. The updated release reads: AGILENT TO SHOWCASE NEXT-GENERATION DIGITAL PATHOLOGY SOLUTIONS AT USCAP 2025 (NYSE: A) is excited to announce its participation at the upcoming , which will be held March 22-27, 2025, in Boston. At the conference, Agilent will highlight innovative digital pathology solutions designed to enhance diagnostic accuracy and efficiency. In pathology, Agilent offers comprehensive tissue diagnostic solutions for analyzi...

 PRESS RELEASE

Agilent Research Catalyst Award Presented to Columbia University for P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced that has received an Agilent Research Catalyst (ARC) Award on behalf of , an internationally recognized researcher and physician-scientist specializing in bone marrow transplant (BMT) and cancer cellular immunotherapy. Dr. Muranski is the Director of Cellular Immunotherapy Laboratory at Columbia University Irving Medical Center. He is also an Assistant Professor of Medicine at Columbia University Medical Center, a principal investigator at the Columbia Center for Translational Immunology (CCTI), and a member of the Herbert Irv...

 PRESS RELEASE

Agilent PD-L1 IHC 28-8 pharmDx Receives EU IVDR Certification as a Com...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced its kit has received two new companion diagnostic indications approvals under EU IVDR1, expanding the eligibility of treatment to early-stage non-small cell lung cancer (NSCLC) and previously untreated advanced melanoma patients. These two new indications bring the total indications launched in Europe for PD-L1 IHC 28-8 pharmDx to nine. PD-L1 IHC 28-8 pharmDx is approved for exclusive use with the advanced staining solution. Lung cancer and malignant melanoma are major healthcare concerns worldwide, with lung cancer accountin...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch